Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  2. Addiction Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  3. Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  4. Addiction Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  5. Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  6. Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  7. Addiction Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  8. Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  9. Department of Psychiatry, King AbdulAziz University, Jeddah, Saudi Arabia
  10. Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  11. Corresponding Author: Ahmed N. Hassan, MD, FRCPC, 100 Stokes St, Toronto, ON M6J 1H4 ([email protected]).
  1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. PubMed CrossRef
  2. Koenen KC, Ratanatharathorn A, Ng L, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017;47(13):2260–2274. PubMed CrossRef
  3. Goldstein RB, Smith SM, Chou SP, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51(8):1137–1148. PubMed CrossRef
  4. Janoutová J, Janácková P, Serý O, et al. Epidemiology and risk factors of schizophrenia. Neuroendocrinol Lett. 2016;37(1):1–8. PubMed
  5. Rowland TA, Marwaha S. Epidemiology and risk factors for bipolar disorder. Ther Adv Psychopharmacol. 2018;8(9):251–269. PubMed CrossRef
  6. Krysinska K, Lester D. Post-traumatic stress disorder and suicide risk: a systematic review. Arch Suicide Res. 2010;14(1):1–23. PubMed CrossRef
  7. Rapaport MH, Clary C, Fayyad R, et al. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162(6):1171–1178. PubMed CrossRef
  8. Pietrzak RH, Goldstein RB, Southwick SM, et al. Medical comorbidity of full and partial posttraumatic stress disorder in US adults: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med. 2011;73(8):697–707. PubMed CrossRef
  9. McCauley JL, Killeen T, Gros DF, et al. Posttraumatic stress disorder and co-occurring substance use disorders: advances in assessment and treatment. Clin Psychol (New York). 2012;19(3):283–304. PubMed CrossRef
  10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. Fifth Edition, Text Revision. American Psychiatric Association Publishing; 2022.
  11. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006;2006(1):CD002795. PubMed CrossRef
  12. Lewis C, Roberts NP, Gibson S, et al. Dropout from psychological therapies for post-traumatic stress disorder (PTSD) in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11(1):1709709. PubMed CrossRef
  13. Hill MN, Campolongo P, Yehuda R, et al. Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology. 2018;43(1):80–102. PubMed CrossRef
  14. Hillard CJ, Weinlander KM, Stuhr KL. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience. 2012;204:207–229. PubMed CrossRef
  15. Ney LJ, Matthews A, Bruno R, et al. Cannabinoid interventions for PTSD: where to next? Prog Neuropsychopharmacol Biol Psychiatry. 2019;93:124–140. PubMed CrossRef
  16. Ruehle S, Rey AA, Remmers F, et al. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol. 2012;26(1):23–39. PubMed CrossRef
  17. Ganon-Elazar E, Akirav I. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J Neurosci. 2009;29(36):11078–11088. PubMed CrossRef
  18. Maldonado R, Cabañero D, Martín-García E. The endocannabinoid system in modulating fear, anxiety, and stress
. Dialogues Clin Neurosci. 2020;22(3):229–239. PubMed CrossRef
  19. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–534. PubMed CrossRef
  20. Niyuhire F, Varvel SA, Martin BR, et al. Exposure to marijuana smoke impairs memory retrieval in mice. J Pharmacol Exp Ther. 2007;322(3):1067–1075. PubMed CrossRef
  21. Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–836. PubMed CrossRef
  22. Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):1034–1040. PubMed CrossRef
  23. Lake S, Kerr T, Buxton J, et al. Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? evidence from a population-based cross-sectional study of Canadians. J Psychopharmacol. 2020;34(2):181–188. PubMed CrossRef
  24. Bilevicius E, Sommer JL, Asmundson GJG, et al. Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: results from an American nationally representative study. Depress Anxiety. 2019;36(11):1036–1046. PubMed CrossRef
  25. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
  26. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. PubMed CrossRef
  27. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. PubMed CrossRef
  28. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. 2013. https://web.archive.org/web/20210716121605id_/http://www3.med.unipmn.it/dispense_ebm/2009-2010/Corso%20Perfezionamento%20EBM_Faggiano/NOS_oxford.pdf
  29. Vardell E, Malloy M. Joanna Briggs Institute: an evidence-based practice database. Med Ref Serv Q. 2013;32(4):434–442. PubMed CrossRef
  30. Bonn-Miller MO, Brunstetter M, Simonian A, et al. The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder. Cannabis Cannabinoid Res. 2022;7(2):214–223. PubMed CrossRef
  31. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559–564. PubMed CrossRef
  32. Elms L, Shannon S, Hughes S, et al. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25(4):392–397. PubMed CrossRef
  33. Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014;46(1):73–77. PubMed CrossRef
  34. Pillai M, Erridge S, Bapir L, et al. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry. Expert Rev Neurother. 2022;22(11-12):1009–1018. PubMed CrossRef
  35. Allan NP, Ashrafioun L, Kolnogorova K, et al. Interactive effects of PTSD and substance use on suicidal ideation and behavior in military personnel: Increased risk from marijuana use. Depress Anxiety. 2019;36(11):1072–1079. PubMed CrossRef
  36. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(9):1174–1180. PubMed CrossRef
  37. Johnson MJ, Pierce JD, Mavandadi S, et al. Mental health symptom severity in cannabis using and non-using veterans with probable PTSD. J Affect Disord. 2016;190:439–442. PubMed CrossRef
  38. Roitman P, Mechoulam R, Cooper-Kazaz R, et al. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014;34(8):587–591. PubMed CrossRef
  39. Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. PLoS One. 2021;16(3):e0246990. PubMed CrossRef
  40. Bonn-Miller MO, Boden MT, Vujanovic AA, et al. Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychol Trauma. 2013;5(2):193–200. CrossRef
  41. Livingston NA, Farmer SL, Mahoney CT, et al. Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychol Addict Behav. 2022;36(2):131–143. PubMed CrossRef
  42. Manhapra A, Stefanovics E, Rosenheck R. Treatment outcomes for veterans with PTSD and substance use: impact of specific substances and achievement of abstinence. Drug Alcohol Depend. 2015;156:70–77. PubMed CrossRef
  43. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–588. PubMed CrossRef
  44. Botsford SL, Yang S, George TP. Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential. Am J Addict. 2020;29(1):9–26. PubMed CrossRef
  45. Rehman Y, Saini A, Huang S, et al. Cannabis in the management of PTSD: a systematic review. AIMS Neurosci. 2021;8(3):414–434. PubMed CrossRef
  46. Wilkinson ST, Radhakrishnan R, D’Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. J Clin Psychiatry. 2016;77(8):1050–1064. PubMed CrossRef
  47. Steenkamp MM, Blessing EM, Galatzer-Levy IR, et al. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017;34(3):207–216. PubMed CrossRef
  48. LaFrance EM, Glodosky NC, Bonn-Miller M, et al. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord. 2020;274:298–304. PubMed CrossRef
  49. Feinberg I, Jones R, Walker JM, et al. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther. 1975;17(4):458–466. PubMed CrossRef
  50. Feinberg I, Jones R, Walker J, et al. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther. 1976;19(6):782–794. PubMed CrossRef
  51. Schierenbeck T, Riemann D, Berger M, et al. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381–389. PubMed CrossRef
  52. Bolla KI, Lesage SR, Gamaldo CE, et al. Sleep disturbance in heavy marijuana users. Sleep. 2008;31(6):901–908. PubMed CrossRef
  53. Ross RJ, Ball WA, Dinges DF, et al. Rapid eye movement sleep disturbance in posttraumatic stress disorder. Biol Psychiatry. 1994;35(3):195–202. PubMed CrossRef
  54. Singareddy RK, Balon R. Sleep in posttraumatic stress disorder. Ann Clin Psychiatry. 2002;14(3):183–190. PubMed CrossRef
  55. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Includes ICD-9-CM Codes Effective October 1, 1996. Fourth Edition. 1998.
  56. Weathers FW, Bovin MJ, Lee DJ, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess. 2018;30(3):383–395. PubMed CrossRef
  57. Gradus JL, Qin P, Lincoln AK, et al. Posttraumatic stress disorder and completed suicide. Am J Epidemiol. 2010;171(6):721–727. PubMed CrossRef
  58. Sher L. Neurobiology of suicidal behavior in post-traumatic stress disorder. Expert Rev Neurother. 2010;10(8):1233–1235. PubMed CrossRef
  59. Vinod KY. Role of the endocannabinoid system in the neurobiology of suicide. In: Dwivedi Y, ed. The Neurobiological Basis of Suicide. CRC Press/Taylor & Francis; 2012.
  60. Hungund BL, Vinod KY, Kassir SA, et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry. 2004;9(2):184–190. PubMed CrossRef
  61. Pava MJ, den Hartog CR, Blanco-Centurion C, et al. Endocannabinoid modulation of cortical up-states and NREM sleep. PLoS One. 2014;9(2):e88672. PubMed CrossRef
  62. Pava MJ, Makriyannis A, Lovinger DM. Endocannabinoid signaling regulates sleep stability. PLoS One. 2016;11(3):e0152473. PubMed CrossRef
  63. Chagas MH, Crippa JA, Zuardi AW, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013;27(3):312–316. PubMed CrossRef
  64. Hsiao YT, Yi PL, Li CL, et al. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology. 2012;62(1):373–384. PubMed CrossRef
  65. Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials. Front Neurosci. 2018;12:502. PubMed CrossRef
  66. Carabellese F, Candelli C, Martinelli D, et al. Cannabis use and violent behaviour: a psychiatric patients cohort study in southern Italy. Riv Psichiatr. 2013;48(1):43–50. PubMed
  67. Norström T, Rossow I. Cannabis use and violence: is there a link? Scand J Public Health. 2014;42(4):358–363. PubMed CrossRef
  68. Sorkhou M, Johnstone S, Kivlichan AE, et al. Does cannabis use predict aggressive or violent behavior in psychiatric populations? a systematic review. Am J Drug Alcohol Abuse. 2022;48(6):631–643. PubMed CrossRef
  69. Dellazizzo L, Potvin S, Dou BY, et al. Association between the use of cannabis and physical violence in youths: a meta-analytical investigation. Am J Psychiatry. 2020;177(7):619–626. PubMed CrossRef
  70. Bayrakçı A, Sert E, Zorlu N, et al. Facial emotion recognition deficits in abstinent cannabis dependent patients. Compr Psychiatry. 2015;58:160–164. PubMed CrossRef
  71. Castro-Vale I, Severo M, Carvalho D. Lifetime PTSD is associated with impaired emotion recognition in veterans and their offspring. Psychiatry Res. 2020;284:112666. PubMed CrossRef
  72. Zimmermann K, Walz C, Derckx RT, et al. Emotion regulation deficits in regular marijuana users. Hum Brain Mapp. 2017;38(8):4270–4279. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now